The Nigerian senate urging the federal and state governments to ensure that life-saving antidotes, including snake antivenom, are stocked and accessible across hospitals looks like progress, but Nigeria has an emergency readiness problem, not a snakebite problem, really.
Development Diaries reports that the senate, this week, moved a motion urging the federal and state governments to ensure that life-saving antidotes, including snake antivenom, are stocked and accessible across Nigeria’s hospitals following the death of Ifunanya Nwagene.
The motion also wants regulators to make antidote availability a condition for licencing private hospitals. It even stretches into Nigeria’s famous ‘building code universe’, recommending that homes include Non-Return Valves (NRVs) to stop snakes and rodents from entering through drainage systems.
But will this become actual protection, or just another ‘the senate has urged…’ story that evaporates as soon as the cameras pack up?
Snakebite is one of several time-critical emergencies Nigerians face. Others include scorpion stings, poisoning, and overdoses, with people dying fast when the system responds slowly.
The senate’s debate, triggered by the public outrage over Ifunanya’s death, only confirms what families across Nigeria already know. The ‘golden hour’ after an emergency is not poetic language; it is governance. It tells whether a country can respond to predictable crises without forcing families to turn into emergency logisticians.
But motions alone do not fix the gaps killing people.
The first gap is Nigeria’s chaotic supply chain. Antivenom is not paracetamol, because it requires forecasting, storage integrity, redistribution systems, and accountability.
So, a motion cannot conjure those systems into existence; budgets and procurement rules do.
Then there is the ‘right drug’ problem. Not every antivenom works for every species, and not every product in the Nigerian market is even reliable, with the WHO estimating between 81,000 and 138,000 global snakebite deaths annually, yet Nigeria still treats stocking ‘something called antivenom’ as success.
Affordability is the third gap. Even when a facility has the antidote, families often cannot afford it, with survival becoming a financial negotiation.
And the biggest gap, the Nigerian classic, is implementation, because we are world-class at issuing directives and world-class at not enforcing them. Inspection systems fail, sanctions are rare, and paper compliance becomes the performance.
The Federal Ministry of Health and Social Welfare is responsible for emergency care standards and supply-chain architecture, while state ministries manage procurement and facility readiness. These regulators must inspect and sanction where necessary.
As for hospitals, they must keep transparent inventories and have staff trained for emergencies, with agencies like the National Orientation Agency (NOA) running public education in a language people can use.
There is an equity side to this story, too. Rural and peri-urban communities face the highest exposure and longest travel times. Poor households delay care because cost decisions come before survival decisions, and women bear the invisible burden of caregiving and economic shock.
So yes, Nigerians should welcome the senate’s concern, but we must ask hard questions.
Which antidotes are mandatory for each level of hospital? Who pays for stocking? Will health insurance cover emergency antidotes? How often will inspections happen, and what happens when a hospital claims to have stock but does not? Will the new building code recommendation become enforceable, or will it just be one more line item inside a code that few people follow?
